Skip to Main Content
Contribute Try STAT+ Today

Will a change at the top of the US Securities and Exchange Commission mean that drug makers will not be so readily fined for paying bribes overseas as they seek to boost sales of their medicines?

Such speculation emerged after the Trump transition team last week tapped Jay Clayton, a partner at the Sullivan & Cromwell law firm, to head the agency. And the chatter about his views on the Foreign Corrupt Practices Act stems from a 2011 paper written by a New York City Bar Association committee, which he chaired, that maintained the law was causing “lasting harm” to US companies.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.